Working Toward Worldwide Leadership

The TAXUS program began seven years ago as a promise to revolutionize the treatment of coronary artery disease. Today we are turning that promise into reality: the TAXUS Express² paclitaxel-eluting coronary stent system has proved safe and effective in reducing restenosis in patients around the world.

In 2003 and early 2004, we achieved a number of significant milestones, including:

• Approval from the U.S. Food and Drug Administration to sell the TAXUS system in the United States, a culmination of years of hard work by many people at Boston Scientific;

• A successful U.S. launch characterized by our ability to meet market demand with unconstrained supply. Quantities available at launch exceeded our original plan and will be maintained, with an initial monthly target production capacity of 100,000 units;